+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Granules India Ltd (GRANULES) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 52 Pages
  • August 2023
  • Region: India
  • GlobalData
  • ID: 4391494
Granules India Ltd (GRANULES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Granules India Ltd (Granules) is a pharmaceutical manufacturing company, that manufactures active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Ibuprofen, Paracetamol, Metformin, Guaifenesin and Methocarbamol. It has premier facilities for the manufacture of APIs, PFIs and FDs. With offices in India, the US, and the UK, the company offers products and solutions to over 80 countries across the world. Granules also provides contract research and manufacturing services. The company's key clients include generic and branded pharmaceutical companies. Granules is headquartered in Hyderabad, Telangana, India.

Granules India Ltd Key Recent Developments

  • Aug 04, 2023: Granules Pharmaceuticals, Successfully Completes USFDA Postmarketing Adverse Drug Experience (PADE) Inspection With Zero Observations
  • Jul 14, 2023: Granules India Limited Announced Approval for the Store Brand OTC Equivalent of Advil Dual Action Tablets
  • May 22, 2023: Granules India earnings conference call for Q4 and financial year ended on March 31, 2023
  • May 16, 2023: Granules India appoints Mr. Kapil Kumar Mehan as additional director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Granules India Ltd - Key Facts
  • Granules India Ltd - Key Employees
  • Granules India Ltd - Key Employee Biographies
  • Granules India Ltd - Major Products and Services
  • Granules India Ltd - History
  • Granules India Ltd - Company Statement
  • Granules India Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Granules India Ltd - Business Description
  • Business Segment: Active Pharmaceutical Ingredients (API)
  • Overview
  • Performance
  • Business Segment: Finished Dosages (FD)
  • Overview
  • Performance
  • Business Segment: Pharmaceutical Formulation Intermediates (PFI)
  • Overview
  • Performance
  • Geographical Segment: Outside India
  • Performance
  • Geographical Segment: Within India
  • Performance
  • R&D Overview
  • Granules India Ltd - Corporate Strategy
  • Granules India Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Granules India Ltd - Strengths
  • Granules India Ltd - Weaknesses
  • Granules India Ltd - Opportunities
  • Granules India Ltd - Threats
  • Granules India Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Granules India Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 04, 2023: Granules Pharmaceuticals, Successfully Completes USFDA Postmarketing Adverse Drug Experience (PADE) Inspection With Zero Observations
  • Jul 14, 2023: Granules India Limited Announced Approval for the Store Brand OTC Equivalent of Advil Dual Action Tablets
  • May 22, 2023: Granules India earnings conference call for Q4 and financial year ended on March 31, 2023
  • May 16, 2023: Granules India appoints Mr. Kapil Kumar Mehan as additional director
  • Mar 29, 2023: Granules Consumer Health inaugurates its packaging facility in the U.S.
  • Mar 17, 2023: Granules India Announces Mr. Robert George Cunard step down as Independent Director
  • Jan 24, 2023: Granules India Announces Financial Results for the Quarter and Nine Months Ended December 31, 2022
  • Dec 06, 2022: Global pharmaceuticals manufacturer Granules India to expand in Manassas
  • Nov 30, 2022: Granules India to establish pharmaceutical packaging facility in Virginia, creating 57 new jobs
  • Aug 26, 2022: Granules : Update on GPI facility
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Granules India Ltd, Key Facts
  • Granules India Ltd, Key Employees
  • Granules India Ltd, Key Employee Biographies
  • Granules India Ltd, Major Products and Services
  • Granules India Ltd, History
  • Granules India Ltd, Subsidiaries
  • Granules India Ltd, Key Competitors
  • Granules India Ltd, Ratios based on current share price
  • Granules India Ltd, Annual Ratios
  • Granules India Ltd, Interim Ratios
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Granules India Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Granules India Ltd, Performance Chart (2019 - 2023)
  • Granules India Ltd, Ratio Charts
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bal Pharma Ltd
  • Atul Ltd
  • Divi's Laboratories Ltd
  • BASF India Ltd
  • Teva Pharmaceutical Industries Ltd
  • Suven Life Sciences Ltd
  • Hikal Ltd
  • Lyka Labs Ltd
  • Biocon Ltd
  • Ind-Swift Laboratories Ltd
  • Lyka Labs Ltd
  • Divi's Laboratories Ltd
  • Atul Ltd
  • Bal Pharma Ltd
  • Hikal Ltd
  • Teva Pharmaceutical Industries Ltd
  • Suven Life Sciences Ltd
  • BASF India Ltd
  • Ind-Swift Laboratories Ltd